CRL - Charles River Laboratories International Inc.
(NaN%)
SNP 500
Hold
Moderate Growth and Improving
55%
based on last 5 year data.
Income Statement is MODERATE
Revenue Growth is 98.19%
Operating Income Growth is -18.54%
Net Income Growth is -13.03%
Earnings Per Share (EPS) Growth is -13.31%
Net Margin is 10.17%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 1.48
Debt Ratio is 0.52
Current Debt to Net Income Ratio is 0.0
Total Debt to Total Assets Ratio is 0.29
Cash Flow is STRONG
Cash from Operations Growth is 14.11%
Capital Expenditure is High
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Charles River Laboratories International Inc. (CRL) - https://www.criver.com/
charles river provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. #drugdiscovery #biotech #biotechnology #pharmaceuticals #croExchange - NEW YORK STOCK EXCHANGE INC.
Industry - Research and Development in Biotechnology
Sector - Professional, Scientific, and Technical Services
CEO - James Foster
Employees - 12,903
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2024 and future.
Know the Stock © 2024 and future.